Prostaglandin E2 Mediates Cardiorespiratory Disturbances during Infection in Neonates  by Siljehav, Veronica et al.
Prostaglandin E2 Mediates Cardiorespiratory Disturbances during Infection
in Neonates
Veronica Siljehav, MD, PhD*, Annika M. Hofstetter, MD, PhD*, Kristin Leifsdottir, MD, and Eric Herlenius, MD, PhD
Objective To determine whether infection, with associated eicosanoid release, is a main cause of respiratory
disruption in neonates, by measuring levels of prostaglandin E2 (PGE2) and its metabolite (PGEM) in cerebrospinal
fluid (CSF).
Study design Of 59 eligible infants, 25 preterm infants (mean gestational age, 28  0.5 weeks) and 22 full-term
infants (mean gestational age, 40 0.5 weeks) from a level 3 neonatal intensive care unit and the general maternity
neonatal ward were enrolled prospectively. Infants with a condition that can cause secondary apnea were
excluded. Cardiorespiratory disturbances, such as apnea, bradycardia, and desaturation (ABD) events, were quan-
tified. All infants were subjected to standard laboratory analysis of blood and CSF concentrations of biomarkers,
including PGE2 and PGEM, within 24 hours of lumbar puncture, which were correlated with ABD events and
culture-verified infections.
Results PGEM levels were highest in infants with culture-verified sepsis andmeningitis (P < .01). In infants without
culture-verified bacterial infections, PGEM levels were higher in preterm infants compared with term infants
(P < .05). The numbers of desaturation events and apnea events in neonates were positively associated with
PGE2 levels in CSF (P < .05).
Conclusion PGE2 and PGEM are rapidly elevated in CSF during an infectious event and may explain cardiorespi-
ratory disturbances, which are themajor presenting symptoms of neonatal infections. PGE2 and PGEMare released
during bacterial infections and could serve as biomarkers for sepsis and autonomic dysfunction in neonates. (J Pe-
diatr 2015;167:1207-13).
S
epsis and meningitis are major causes of morbidity and mortality in the neonatal population. Dominant presenting fea-
tures of septicemia in preterm infants include increasing apnea (55%),1 bradycardia, and desaturation (ABD) events.2,3
Prostaglandin E2 (PGE2), induced by the proinflammatory cytokine interleukin (IL)-1b, impairs respiration during
infection.2
IL-1b prolongs the duration of larynx stimulation-induced apnea and alters resuscitation.4,5 The concentration of IL-1b in
pharyngeal secretions from human infants is positively correlated with the clinical severity of apnea.6 Furthermore, PGE2 is
involved in apnea in mice7 and lambs.8 In humans, a well-known side effect of PGE2 therapy is apnea. Moreover, in human
neonates, PGE2 is rapidly released into the cerebrospinal fluid (CSF) during acute hypoxia and is correlated with the degree
of birth asphyxia.9
The PGE2 signaling pathway is induced by IL-1b binding to type I receptors on the vascular endothelial cells of the blood-
brain barrier, resulting in a release of PGE2 in the brainstem regions involved in respiratory control.
10 In turn, PGE2 binds to the
prostaglandin E receptor type 3 (EP3R) on respiratory rhythm-generating neurons in the ventrolateral medulla and depresses
their activity.11,12 An attenuated release of PGE2 protects against respiratory depression during infectious and hypoxic events.
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ABD Apnea, bradycardia, and
desaturation
AI Apnea index
CRP C-reactive protein
CSF Cerebrospinal fluid
EP3R Prostaglandin E receptor type 3
GA Gestational age
GMNW General medical neonatal ward
IL Interleukin
NICU Neonatal intensive care unit
PGE2 Prostaglandin E2
PGEM Prostaglandin E2 metabolite
ROC Receiver operating characteristic
WBC White blood cell
1207
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 167, No. 6aim was to determine whether levels of PGE2 and PGEM are
associated with the severity of autonomic dysfunction during
infectious events in a neonatal population.
Methods
The study was performed in accordance with European
Community guidelines. The regional Ethics Committees of
the Karolinska Institutet and Stockholm County approved
the study. Informed written consent was obtained from par-
ents of the enrolled patients.
A total of 59 infants from the neonatal intensive care unit
(NICU) and control infants from the general medical
neonatal ward (GMNW) at Karolinska University Hospital
were recruited with written consent. We included 25 preterm
infants (mean gestational age [GA], 28 0.5 weeks; 15 males,
10 females) and 22 full-term infants (mean GA,
40 0.5 weeks; 11males, 11 females), who were enrolled pro-
spectively (Table I). The infants underwent lumbar puncture
for clinical indications, such as ABD events, suspected
infection, or neurologic investigations. Infants with
intraventricular hemorrhage (grade $2), periventricular
leukomalacia, electroencephalogram-verified seizures, or
major congenital abnormalities giving rise to secondary
apnea were excluded. Pertinent medical information was
collected, including neonatal delivery data, medical
conditions, medications, laboratory data, respiratory
therapy, and occurrence of ABD events. Invasive
procedures, including intubation and central line
placement, occurring at the time of or during the week
before enrollment, were documented.
CSF Collection and Analysis
After CSF was collected for routine laboratory analysis, an
additional 0.75-1.5 ml of CSF per infant was obtained for
research purposes. The CSF samples were initially stored at
18C and subsequently transferred to a 80C freezer.
Before analysis, the samples were thawed, and 20-mL aliquots
were prepared.
CSF samples were analyzed for PGE2 and PGEM using a
standardized enzyme immunoassay protocol (Cayman
Chemicals, Ann Arbor, Michigan).9 Standard laboratory
analysis of CSF was also performed to detect the presence
of red blood cells, glucose, protein, and white blood cells
(WBCs), including monocyte and leukocyte counts. Blood
concentrations of infectious markers (C-reactive proteinTable I. Characteristics of preterm and term infants in the N
n GA, wk + d Apgar 1 score Apgar 5 s
Preterm, NICU 25 28  0.5 5  0.5 7  0
Term, NICU 14 40  0.6 7  0.7 9  0
Term, GMNW 8 40  0.8 8  0.9 9  0
PNd, postnatal day.
Apgar score tended to be lower in preterm infants in all observation periods (1, 5, and 10 minutes). Lu
CRP differed between groups. Data are presented as mean  SEM.
*P < .05.
1208[CRP] and WBCs) were measured within 24 hours of the
lumbar puncture. Serum and CSF culture results were
documented.
Cardiorespiratory Recordings
Seventeen infants underwent noninvasive cardiorespiratory
recording within 22 hours of lumbar puncture (mean
recording time, 9:35  2:27 hours) using the KIDS event
monitoring system (Hoffrichter, Schwerin, Germany). CRP
and Apnea Index (AI) data from some of these infants
(n = 12) have been presented previously, but 3 of these in-
fants were excluded from the present study because they
did not match preset inclusion criteria.7 Impedance pneu-
mography detected chest wall movements as an indicator
of respiratory volume changes, and a 3-lead electrocardio-
gram detected heart rate variability. The monitor was pro-
grammed to record all events exceeding set threshold
values. An apnea-hypopnea event was defined as a $10-
second reduction in respiratory rate by 84% from the previ-
ous mean value of 25 seconds, a preset definition in the KIDS
monitoring system.2,7 Bradycardia was defined as a heart rate
of <80 bpm. Mean heart rate and respiratory frequency dur-
ing the 15 and 30 seconds immediately before or apnea or
bradycardia, respectively, were recorded with the KIDS
monitor. The 60-second periods both before and after the
events were stored in the monitor’s memory.Data and Statistical Analyses
Each cardiorespiratory recording was analyzed to assess ABD
events. Events over time were defined as the AI (AI = apneas-
hypopneas/hour) and the bradycardia index (bradycardias/
hour).2 Baseline respiratory frequency and heart rate were
also determined. All movement artifacts were excluded
from analysis. Cardiorespiratory data were correlated with
infant medical data, including GA, postnatal age, presence
of culture-verified bacterial infection or viral infection, med-
ical diagnoses, and factors that could affect cytokine concen-
trations (ie, intubation, indomethacin therapy, perinatal
asphyxia, hypoxic-ischemic encephalopathy, and corticoste-
roid administration). An investigator blinded to the labora-
tory and the eicosanoid analyses performed retrospective
collection of ABD events in the abstracted medical records.
Cardiorespiratory data were also correlated with CSF con-
centrations of PGE2 and PGEM.
Unless stated otherwise, clinical data are presented asmean
and 95% CI or IQR. Parametric clinical data were assessedICU and term infants in the GMNW
core Apgar 10 score Lumbar puncture, PNd CRP, mg/L
.4 8  0.3 15  2* 52  9
.6 9  0.5 5  3 83  15*
.8 10  0.6 1  4 16  15
mbar puncture was performed at a later PNd in preterm infants compared with term infants. The
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Figure 1. A, Comparing term and preterm infants without
culture-verified bacterial infections, PGEM levels were higher
in the preterm infants. PGEM levels did not differ in infants
whowere intubated or had a central line.B, PGEM levels were
higher in the CSF of infants with culture-positive infections. C,
CRP levels were highest in infants in the NICU, but could not
differentiate sepsis and meningitis from other clinical cases.
D, ROC curves show better sensitivity and specificity to
infection for PGEM level compared with CRP level. Data are
presented as mean  SEM. *P < .05; **P < .01.
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Levene test, and if positive parametric data was tested by us-
ing Welch’s test and nonparametric by using Wilcoxon c2
test. A generalized linear model was used to identify the vari-
ables associated with PGE2 level. Correlation analyses were
performed without making distinction between term and
preterm infants. Receiver operating characteristic (ROC)
curves were calculated to illustrate and evaluate the diag-
nostic (prognostic) performance of PGE2, PGEM, and CRP
in relation to ABD events and culture-verified bacterial infec-
tions. In all cases, P values of <.05 were considered statisti-
cally significant.Results
Age, birth weight, and time to lumbar puncture differed be-
tween the groups. Apgar scoring was performed to assess the
infants’ condition at 1, 5, and 10 minutes after birth. Charac-
teristics of the study groups are summarized in Table I.
Preterm infants had higher levels of PGEM relative to term
infants (P < .05, Student t test) (Figure 1, A). PGE2 and CRP
levels were not affected by GA (Table II; available at www.
jpeds.com), and PGEM levels were not affected by recent
intubation or central catheter insertion.
Nonetheless, because of the small sample size, the results
were not adjusted for GA. The highest PGE2 and PGEM levels
were seen in the infants with culture-confirmed bacterial in-
fections. PGEM levels were higher in infants with culture-
verified meningitis and sepsis compared with those without
either condition in the NICU or GMNW (P < .05
and <.01, respectively, c2 test, power 75%) (Figure 1, B).
CRP levels did not differentiate culture-confirmed bacterial
infection from other infections. CRP levels were higher in
infants in the NICU compared with those in the GMNW
(P < .05, c2 test) (Figure 1, C and Table I). The ROC
curves of PGEM and CRP levels show that PGEM level was
both more specific and more sensitive in discriminating
culture-positive bacterial infections from other infections
(Figure 1, D). CSF protein levels were elevated in preterm
infants compared with term infants; this difference
remained after excluding infants with sepsis or meningitis
owing to the potential for confounding16 (Tables I and III
and Figure 1, C and D; Table III available at www.jpeds.
com). Estimation of the overall predictive value for
culture-verified infection by the area under the ROC curve
showed positive predictive values of 75% for PGEM level,
but only 63% for CRP level. Bacteria and viral culture data
are presented in Table IV (available at www.jpeds.com).
Both PGE2 and PGEM levels correlated with CRP levels
(R2 = 0.24, linear fit line; P < .05; n = 28 and R2 = 0.24, linear
fit line; P < .01; n = 35, respectively) (Figure 2; available at
www.jpeds.com). No correlations were found between
serum or WBCs in the CSF and PGE2 or PGEM levels.
Desaturation events in infants in the NICUwere correlated
with PGE2 levels and tended to correlate with PGEM levels
(R2 = 0.21, linear fit line; P < .01; n = 35 and R2 = 0.08, linearInfection in Neonates 1209
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available at www.jpeds.com). AI, that was monitored in 8
infants, correlated with PGE2 levels (P < .05, c2 test)
(Figure 3, C). In addition, shorter apnea periods (10-
14 seconds) tended to correlate with PGEM levels, but did
not reach significance in our study population (R2 = 0.38,
linear fit line; P = .06; n = 9). The 4 infants treated with
indomethacin within 6 hours before lumbar puncture had
lower PGE2 levels, but not lower PGEM levels.
Infants who experienced an ABD event before lumbar
puncture had higher PGEM levels relative to infants investi-
gated because of other indications, such as neurologic inves-
tigations or increased CRP levels (P < .05, Student t test)
(Figure 4, A). The ROC curves of PGEM and CRP levels
showed that PGEM levels were both more specific and
more sensitive when correlated with ABD events (Figure 4,
B). In terms of overall predictive value for ABD events,
estimation by the area under the ROC curve showed
positive predictive values of 78% for PGEM level, but only
59% for CRP level.Figure 4. A, Infants who presented with ABD events before
lumbar puncture had increased PGEM levels compared with
infants investigated for other reasons. B, ROC curves illus-
trate greater sensitivity and specificity to ABD events for
PGEM level compared with CRP level. Data are presented as
mean  SEM. *P < .05.Discussion
Here we have demonstrated that in neonates, levels of PGE2
and PGEM in CSF are inversely correlated with GA and are
positively correlated with the presence and severity of ABD
events and infection. These findings provide an understand-
ing of the prostaglandin mechanism underlying autonomic
dysfunction in neonates. Moreover, our data suggest that
PGE2 and PGEM may be promising novel biomarkers
for infections and cardiorespiratory dysfunction in young
infants.
Neonatal bacterial infections carry high rates of mortality
andmorbidity.17 Early diagnosis is difficult because the initial
clinical signs are nonspecific.1 Consequently, physicians
frequently prescribe antibiotic treatment for newborn in-
fants, out of concern for possibly overlooking a life-
threatening infection.18 The initiation of treatment is often
based on a combination of risk factors for infection, clinical
presentation, and inflammatory markers. The duration of
antibiotic therapy potentially could be minimized by adding
PGEM to the decision making algorithm, particularly for in-
fants at low risk of sepsis, as has been shown with other
proinflammatory markers.16 Blood culture is the traditional
gold standard for diagnosing infections; however, obtaining
results can take up to several days, and data may be inconclu-
sive.19 Thus, inflammatory markers are often used in making
decisions regarding therapeutic interventions. Standard
methods for the evaluation of inflammatory status (eg, mea-
surement of CRP and WBC levels) have proven accurate for
establishing the degree of infection, if repetitive measure-
ments are performed days apart20; however, they have only
limited sensitivity during the early phase of the disease.21
Our present data also illustrate that CRP is an unreliable
biomarker and cannot distinguish bacterial infection from
other infections (Figure 1, C).1210Both PGEM and PGE2 levels were associated with CRP
level (Figure 2). Our results demonstrate that compared
with CRP, PGEM correlates better with culture-verified
infection and is better able to predict whether or not the
infection is bacterial (Figure 1, B and D). However, a high
PGEM level does not always indicate infection. Because of
the rapid metabolism of PGE2 in blood (ie, only 3%
remains at 1.5 minutes after administration),22 the use of
blood samples is limited. PGEM has the advantage of being
accumulated more stably into the bloodstream than PGE2,
but it still has a short half-life in blood compared with
plasma (t1/2 = 8 min in blood, 45 min in plasma),
22
making CSF more suitable for analysis. PGEM levels are
higher than PGE2 levels in biological fluids.
23 PGEM is
catabolized enzymatically from PGE2 by stepwise oxidation
and reduction into 13,14-dihydro-15-keto PGE2. In
contrast, PGE2 is a bioactive mediator of inflammation and
has a rapid onset of action (within hours).24 It also has a
short half-life in most biological fluids (t1/2 = 5 minutes in
plasma).25 Thus, both PGE2 and PGEM may be useful
biomarkers, more precise and more sensitive than CRP and
WBCs for detecting bacterial infections. Because these
molecules are detectable early in the course of illness, they
can more quickly predict inflammation. A recent reviewSiljehav et al
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although some promising biomarkers may aid the
diagnosis of infection, the biomarkers investigated to date
are far too expensive and not sufficiently selective for
discerning use.26 We recognize that PGEM level alone is
not sufficient to determine whether a neonatal infant has
an infection or is prone to experience ABD events;
nonetheless, our data suggest that analysis of PGEM level,
in combination with analysis of established biomarkers or
ABD monitoring, could be a promising biomarker to assist
in the diagnosis of infection.
Apnea of prematurity, even without associated infection, is
considered a risk factor for brain injury and developmental
disorders in infants.27 Neonatal sepsis is associated with
decreased normal heart rate variability, even before clinical
manifestations of sepsis become evident.28 We previously
described the mechanism behind inflammatory-induced ap-
nea in neonatal mice via the PGE2-induced pathway
7; howev-
er, this mechanism had not been thoroughly explored in
human infants until the present study. CRP level, for its
part, correlates with autonomic dysfunction,29 but the detec-
tion of CRP is delayed30 and would not affect the decision of
initial observation and treatment.
PGE2 has evolved as a potential biomarker for autonomic
dysfunction in neonates.7 Our results suggest that PGE2 level
correlates with desaturation events, as does PGEM level,
although not reaching the level of significance in the present
study (P = .08) (Figure 3, A and B). This correlation is not
seen with either plasma CRP or WBC count. CSF proteins
and WBCs are not associated with ABD events. A
limitation concerning the associations between ABD events
in the infants treated in the NICU, who did not undergo a
KIDS event recording, is that these data are dependent on
nurse or physician surveillance and recordings documented
in the patient records. Given that approximately one-half
of all events are not documented, the zero values are likely
the most unreliable.31 Nonetheless, when using our more
standardized KIDS event monitoring, the results support
the hypothesis that PGE2 level is directly related to and
may explain the increased incidence of ABD events in the
neonate during infection and other inflammatory events
(Figure 3, C). Moreover, infants who underwent lumbar
puncture because of ABD events had increased PGEM
levels (Figure 4, A).
In the present study, we controlled for factors that could
increase inflammatory variables prior to enrolment, such as
intubation.32 However, these factors did not affect the results.
These findings further strengthen our hypothesis supporting
the PGE2 pathway as a key player in regulating respiration in
the neonate.7,11,13 PGE2 impairs respiratory effort and in-
duces apneas in neonates through its actions on the EP3R
present in the brainstem respiratory-related regions.11
Within the blood-brain barrier, PGE2 decreases brainstem
network activity through its postsynaptic actions to reduce
excitatory synaptic transmission,11 likely through PGE2-
induced hyperpolarization via EP3R expressed in neurons.
PGE2 release in the vicinity of respiratory-related neuronsProstaglandin E2 Mediates Cardiorespiratory Disturbances duringin the brainstem is the result of either an inflammatory
response to IL-1b or hypoxia.24,33 The expression of micro-
somal prostaglandin E synthase-1, the enzyme enabling
PGE2 release in the brainstem, increases during an anoxic
event and can affect outcomes13; thus, not only PGE2 and
PGEM levels, but also microsomal prostaglandin E
synthase-1 activity, might be a potential target of apnea man-
agement.13 PGE2 production is inhibited by indomethacin, a
drug used in the NICU setting to treat patent ductus arte-
rious.34 In the present study, indomethacin lowered PGE2
levels, as expected. PGEM levels were not affected, likely re-
flecting PGE2 levels before indomethacin treatment, owing
to the longer half-life of PGEM.
Preterm infants had higher PGEM levels than term infants
(Figure 1, A). PGE2 exerts multiple effects on the neonatal
kidney, particularly on hemodynamics and the water/
electrolyte balance, but also on its development.35 Preterm
infants have higher levels of urinary PGE2,
36 and the levels
also increase to a greater extent in preterm infants
compared with term infants during the first days of life.37
The increased levels of PGEM in our preterm infants also
could reflect these infants’ immature respiratory regulation,
leading to apnea of prematurity.38 This is because
prostaglandins released by preterm-specific inflammation
give rise to apneas. In addition, apneas give rise to
intermittent hypoxia, and thus this condition on its own
could lead to prostaglandin release.7,13
The present study confirms the relationships among
PGE2, PGEM, infection, and autonomic dysfunction, but
further studies are needed to evaluate the potential and clin-
ical feasibility of these two molecules as biomarkers in the
diagnostic palette for infection. This should be investigated
with a larger study population based on this exploratory
study. Thus, the present data are encouraging but prelimi-
nary. Nonetheless, the rapid synthesis of PGE2 in response
to inflammatory cytokine stimulation makes it particularly
intriguing and possibly useful in the diagnosis and surveil-
lance of infants with infection. In addition to an immediate
release, PGE2 has a short half-life, as noted above. This prop-
erty makes immediate storage of samples and prompt mea-
surement of PGE2 level paramount, to give an indication of
present status. Despite the important role of PGE2 during
inflammation, it is not routinely used as a diagnostic tool
in clinical practice because of its rapid metabolism in vivo
and the inherent difficulties in measurement.
Another limitation of the present study is that PGE2 may
have been metabolized in samples that were not frozen or
analyzed immediately after collection, potentially leading
to underestimation of PGE2 levels. PGEM is more stable
in CSF (t1/2 in plasma = 45 minutes) and also less sensitive
to sample handling; as such, it may better reflect a recent
and ongoing inflammatory process within the CSF environ-
ment. The stable metabolite of PGE2, tetranor-PGEM, is
secreted into urine and has been suggested to be a reliable
inflammatory biomarker.39 Our recent data also suggest
that measurement of urinary tetranor-PGEM, which is
less invasive than lumbar puncture, also may be used as aInfection in Neonates 1211
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the feasibility of using urinary tetranor-PGEM in addition
to 13,14-dihydro-15-keto PGE2 as a biomarker for disease
severity and kinetics in newborns and infants are currently
underway.
In summary, we have demonstrated that PGE2 and its
metabolite reflect ongoing inflammation in neonates, and
have suggested that the increase in PGE2 levels can explain
the cardiorespiratory disturbances that are the presenting
symptoms of infection in neonatal infants. This finding
opens up new avenues for early and precise diagnostic and
therapeutic interventions in preterm and term infants with
suspected infection. n
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Fatty Acids 2014;91:269-75.50 Years Ago in THE JOURNAL OF PEDIATRICSImmunosuppressive Therapy in Persistent Hypocomplementemic
Glomerulonephritis and Lupus Nephritis
West CD, Holland NH, McConville JM, McAdams AJ. J Pediatr 1965;67:1113-22
The authors described 4 children with hypocomplementemic glomerulonephritis (probably membranoprolifera-tive) and 2 children with lupus nephritis treated with immunosuppressive medications (cyclophosphamide,
6-mercaptopurine, and mechlorethamine) in addition to corticosteroids. Only 1 of the 4 patients with hypocomple-
mentemic glomerulonephritis responded well vs both patients with lupus nephritis. This was perhaps the first,
although small, series that described children treated with immunosuppressive medications other than corticosteroids
for lupus nephritis. Immunosuppressive therapy is the standard of care since the 1986 National Institutes of Health
(NIH) study in adults showing the long-term benefit of prednisone + intravenous cyclophosphamide (given monthly
for 6 months and then every 3 months for 2 more years) vs prednisone alone.1 The cyclophosphamide protocol used
by the authors differed much from the NIH protocol in that they gave high dose daily cyclophosphamide (up to
6.6 mg/kg/d) until the white cell count decreased to less than 5000/mm3. Thus, treatment courses were by necessity
short, lasting only 11 to 33 days.
Lupus nephritis in children is more frequent and severe than in adults; thus, aggressive therapy is often needed. Un-
til the early 2000s, the NIH protocol was used in almost all children with substantial lupus nephritis. Owing to the
potential for cyclophosphamide side effects, particularly infertility, secondary malignancies, and hemorrhagic cystitis,
alternatives were sought. Small pediatric studies, with one controlled, have suggested that mycophenylate mofetil may
be an alternative to cyclophosphamide.2 Other immunosuppressive medications used in children include azathio-
prine, cyclosporine, and tacrolimus. The compared effectiveness of these immunosuppressive medications are still un-
clear and not all children respond adequately (often attributable to lack of adherence). Biologics, particularly those
that deplete B-cells or affect their proliferation, have not yet attained their promise in controlled trials. Thus, there
is still an urgent need to develop effective but safer drugs for childhood lupus nephritis than those described first
in The Journal by West et al in 1965.
Philip J. Hashkes, MD, MSc
Pediatric Rheumatology Unit
Shaare Zedek Medical Center
Jerusalem, Israel
http://dx.doi.org/10.1016/j.jpeds.2015.05.012
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Figure 2. Relationships between PGE2 and PGEM levels and
CRP levels in the CSF. A, CRP levels were measured just
before lumbar puncture (mean, 5.6 0.7 hours) and showed a
positive association with PGE2 levels. B, CRP levels also
correlated with PGEM levels both using linear fit (red line) and
2 degree polynominal fit (not shown).
Figure 3. A, Number of desaturations in infants in the NICU
correlated with PGE2 levels. B, PGEM levels and desatura-
tions also tended to be correlated, but the results did not
reach significance. C, Apnea in infants recorded by the KIDS
event monitoring system showed a correlation between AI
and PGE2 levels. Data are presented as mean  SEM.
*P < .05.
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Table II. Characteristics of preterm and term infants, excluding all infants with sepsis or meningitis
n GA, wk + d Apgar 1 score Apgar 5 score Apgar 10 score Lumbar puncture, PNd CRP, mg/L
Preterm 10 27  0.5* 5  0.9 6  0.6 8  0.6 16  2* 34  9
Term 20 40  0.4 7  0.6 9  0.5 9  0.4 2  1 49  12
PNd, postnatal day.
Preterm vs term infants showed a tendency toward lower Apgar scores throughout the first 10 minutes of life, with the lowest scores seen at 1 minute (Apgar 1) and somewhat higher scores seen at
10 minutes (Apgar 10). Lumbar puncture was performed on a later PNd in preterm infants. Data are presented as mean  SEM.
*P < .05.
Table III. Characteristics of inflammatory variables in blood and CSF of preterm and term infants
n WBC, serum, 109/L WBC, CSF, 106/L Monocytes, CSF, 106/L Protein, CSF, g/L
Preterm 19 13  2.2 13  5.5 11  8.0 1.7  0.1*
Term 22 13  2.5 26  14 15  6.7 0.9  0.1
No difference in WBCs in either serum or CSF was seen between preterm and term infants; however, protein levels in CSF were higher in preterm infants. Data are presented as mean  SEM.
*P < .05.
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Table IV. Characteristics of bacterial and viral agents in
blood and CSF cultures
n Positive/negative Pathogen
Bacteria 48 Positive: 13
Negative: 35
CoNS: 6
Staphylococcus aureus: 2
Escherichia coli: 2
Enterococci: 1
Gram-negative streptococci: 1
Group B streptococci: 1
Virus 22 Positive: 1
Negative: 21
Cytomegalovirus: 1
CoNS, = Coagulase-negative staphylococci.
All of the infants were cultured for bacteria blood, CSF, or both. A significant amount of bacteria
was found in 13 of 48 infants, with CoNS the most prevalent bacteria. Virus was cultured from
CSF and blood in 22 of 26 infants. Five infants underwent viral examination of the nasopharynx,
which revealed no virus.
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